History and Milestones
| September 2002: | ► Establish in Shanghai, China ► Support and capital from Hutchison Whampoa Limited ► Initiate botanical opportunities |
| April 2005: | ► Initiate New Chemical Entities (NCE) drug discovery programme |
| May 2005: | ► HMPL-004 Investigational New Drug (IND) application filed with the US Food & Drug Administration |
| May 2006: | ► Parent holding company Hutchison China MediTech Limited successfully completes its initial public offering on London’s Alternative Investment Market |
| November 2006: | ► Initiate oncology collaboration with Merck AG |
| September 2007: | ► Initiate first collaboration with Eli Lilly |
| December 2008: | ► Initiate immunology collaboration with Johnson & Johnson |
| July 2009: | ► Successful completion of HMPL-004 global Phase II clinical trial for Crohn’s diseaseFirst |
| October 2009: |
► internal NCE enters phase I clinical trial in Australia
|
| November 2009: | ► Successful completion of HMPL-004 global Phase II clinical trial for ulcerative colitis |
